Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Otsuka faces the music for generic Abilify, loses battle with FDA

Otsuka has finally lost its battle with the FDA to prevent generics of its antipsychotic Abilify from hitting the market. A federal judge issued a final ruling against the Japanese drugmaker, a little more than a month after regulators opened the door for copycat versions of the meds.

Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazing

Merck's Keytruda gained some regulatory ground in Europe on Friday, nabbing a melanoma recommendation that Opdivo snagged last month. But Opdivo continued to charge ahead, too, winning a nod in lung cancer to help preserve its lead.

Hep C landscape shifts again as BMS combo nabs breakthrough tag

Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed by Merck and Bristol-Myers Squibb.

Relax, J&J--Eliquis may be surging, but Xarelto's safe for now

Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.

Should Eliquis' surge make Xarelto fans very, very afraid? Not really, analyst says

Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.

Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS

The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.

33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme

Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.

Caforio takes CEO role as BMS faces tough year with promising new drugs

Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today at Bristol-Myers Squibb, the question will be how well he speaks dollars and cents.

FDA opens floodgates to generics of Bristol-Myers' Abilify

Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic Abilify, the FDA opened the floodgates to generics of the blockbuster.

Eliquis surge, Abilify's last gasp send BMS sailing to a street-beating Q1

Bristol-Myers Squibb was staring down the end of a barrel at the beginning of this year, bracing for a sales hit as its blockbuster antipsychotic Abilify nears patent expiration. But in an about-face, the drugmaker is celebrating first-quarter earnings that beat the Street's forecasts thanks to promising numbers for some of its newer meds.